CTLA4-eiwit (C-His, mens)

CTLA4

ALPS5, CD, CD152, CELIAC3, CTLA-4, GRD4, GSE, IDDM12

C-His

< 1.0 EU per μg protein as determined by the LAL method.

1.Flow cytometric analysis of anti-CTLA4 CAR expression. 5e5 of anti-CTLA4 CAR-293 cells were stained with 100 μL of 1:50 (2 μL stock solution in 100 μL FACS buffer) of PE-conjugated human CTLA4 Protein (Site-Specific PE Conjugation, His Tag, Cat. No. 11159-H86H-SP) and negative control protein. Non-transduced 293 cells were used as a control (left) . PE signal was used to evaluate the binding activity (QC tested) . 2.Binding activity of PE-conjugated CTLA4 protein to PBMC cells. PBMC cells were stained with FITC conjugated anti-CD3 antibody and PE-conjugated human CTLA4 Protein (Site-Specific PE Conjugation, His Tag, Cat. No. 11159-H86H-SP) and detected by flow cytometry. FITC signal was used to evaluate the content of CD3+ T cells in PBMCs. PE signal was used to evaluate the non-specific binding activity to PBMCs (QC tested) .

Lys 36-Phe 162

The protein has a predicted molecular mass of 17 kDa.

Human